Back to All Services
Our Services
Health Economics Research
At Medicys we partner with, and are preferred suppliers to, many leading health economics firms who focus on measuring and valuing the outcomes of healthcare interventions and who seek to understand how to navigate regulatory frameworks and Health Technology Assessment processes.
Specifically, our pricing and market access specialists recruit, interview and report on our network of local, regional and national payers (and ex payers) and Payer Advising Key Opinion Leaders (PA-KOLs) on topics such as:
- Economic Evaluation
- Cost of illness
- Cost comparison, effectiveness, utility and benefit
- Thresholds and opportunity costs
- Value driven healthcare systems
- Health Policy and Regulatory frameworks
- Approval and labelling
- Pricing Policy and pricing Schemes
- Reimbursement and access
- Insurance systems and national healthcare
- Public spending and national health expenditures
- Procurement systems
- Risk sharing approaches
- Health Technology Assessment
- Systems and structure
- Value framework and dossier format
- Decisions and deliberative processes
Our projects in this discipline usually take the form of Web Assisted Telephone Depth Interviews (WATDIs), online groups or advisory boards (digital or in person).
Related Work
See all Work
health economics research
Clostridioides Difficile Infection
Gain a better understanding of acceptable pricing and of the process and evidence requirements to obtain optimal market access for a potential adult vaccine for the prevention of primary Clostridioides Difficile Infection (CDI) in individuals ≥50 years of age
health economics research
+3
Healthcare assistants / practice nurses, patients, payers
To determine the perceived value of a connected inhaler system in asthma and COPD, including evidence requirements and funding / pricing / market access expectations
health economics research
To understand the requirements for a new PDE4 inhibitor to be reimbursed at appropriate price of new drug, assuming generic X is and is not yet launched
health economics research
+1
regional and national payers
Discuss a new respiratory Product ‘X’, a triple combination for the treatment of asthma and understand how this product might be positioned, gain access and priced in the future treatment landscape. Uncover perceptions around asthma disease burden, unmet needs, current therapies and required evidence to support the approval/reimbursement/funding of Product X in the future
Request a quote
